通过HTR2B介导的内皮保护:通过动脉样硬化中的PI3K/AKT信号通路调节铁死
Delin Li1,2,3, Hui Li1,2, Quanwei Zhao1,2
1Department of Cardiovascularology, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.
Cardiovascular therapeutics
|October 13, 2025
概括
这项研究表明,HTR2B抑制铁亡,这是与动脉样硬化 (AS) 相关的细胞死亡途径. 激活HTR2B通过增强细胞活力和脂质代谢来保护AS的发展.
科学领域:
- 心血管生物学 心血管生物学
- 细胞死亡机制 细胞死亡机制
- 分子医学是分子医学.
背景情况:
- 动脉样硬化 (AS) 是一种慢性炎症性疾病,其特点是动脉中脂质积累和斑块形成.
- 铁,一种由铁积累和脂质过氧化驱动的受调细胞死亡形式,越来越多地被认为是它在AS病变发生中的作用.
- 确定新的治疗点来缓解AS中的铁亡对于改善患者的治疗结果至关重要.
研究的目的:
- 在动脉样硬化背景下阐明HTR2B在铁亡中的作用.
- 调查HTR2B影响铁亡的潜在分子机制.
- 探索针对AS治疗的HTR2B的治疗潜力.
主要方法:
- 人类冠状动脉内皮细胞 (HCAEC) 用氧化低密度脂蛋白 (OX-LDL) 进行治疗,以诱导类似AS的条件和铁亡.
- 评估了关键铁与相关基因 (SLC7A11,GPX4,TfR1,FTH1) 和铁标志物 (LDH,MDA,4-HNE,GSH,铁含量) 的表达水平.
- 在实验室中操纵了HTR2B (过度表达),并评估了它对细胞活力和铁亡的影响.
- 使用ApoE-/-小鼠建立AS模型,并检查HTR2B调制和铁灭抑制对病变发展的影响.
- 研究了PI3K/AKT通路在HTR2B介导的铁灭调节中的参与.
主要成果:
- RNA-Seq分析在OX-LDL治疗的HCAEC中发现了失调的HTR2B表达,这表明它与AS有关.
- 在HCAEC中,OX-LDL暴露诱导了铁亡,其证据是细胞活力降低,SLC7A11和GPX4降低,脂质过氧化增加.
- 过度表达HTR2B逆转了这些影响,改善了细胞活力,减少了铁的积累,并提高了SLC7A11和GPX4.4的调节.
- 发现HTR2B通过PI3K/AKT通路调节铁亡.
- 在体内研究证实,在小鼠模型中,通过激动剂激活HTR2B可以抑制铁亡并减少动脉样硬化病变的发展.
结论:
- 在动脉样硬化中,HTR2B通过抑制铁灭,起到保护作用.
- 该机制涉及HTR2B促进PI3K/AKT通路,这反过来提高细胞活力并减轻铁亡.
- 向HTR2B代表了治疗动脉样硬化的潜在治疗策略.
相关概念视频
01:24Regulation of Angiogenesis and Blood Supply
3.3K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.3K
01:22PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K
01:16Necrosis
6.3K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
6.3K
01:26Atherosclerosis III: Management
319
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
319